University of Leicester
Browse
Authors Final Peer Reviewed Manuscript.pdf (291.5 kB)

Rejuvenation of allogenic red cells: benefits and risks.

Download (291.5 kB)
journal contribution
posted on 2019-03-08, 12:49 authored by H Aujla, M Woźniak, T Kumar, GJ Murphy, REDJUVENATE Investigators
BACKGROUND AND OBJECTIVES: To review preclinical and clinical studies that have evaluated the effects of red cell rejuvenation in vivo and in vitro and to assess the potential risks and benefits from their clinical use. MATERIALS AND METHODS: A systematic review and narrative synthesis of the intervention of red cell rejuvenation using a red cell processing solution containing inosine, pyruvate, phosphate and adenine. Outcomes of interest in vitro were changes in red cell characteristics including adenosine triphosphate (ATP), 2,3-diphosphoglycerate (2,3-DPG), deformability and the accumulation of oxidized lipids and other reactive species in the red cell supernatant. Outcomes in vivo were 24-h post-transfusion survival and the effects on oxygen delivery, organ function and inflammation in transfused recipients. RESULTS: The literature search identified 49 studies evaluating rejuvenated red cells. In vitro rejuvenation restored cellular properties including 2,3-DPG and ATP to levels similar to freshly donated red cells. In experimental models, in vivo transfusion of rejuvenated red cells improved oxygen delivery and myocardial, renal and pulmonary function when compared to stored red cells. In humans, in vivo 24-h survival of rejuvenated red cells exceeded 75%. In clinical studies, rejuvenated red cells were found to be safe, with no reported adverse effects. In one adult cardiac surgery trial, transfusion of rejuvenated red cells resulted in improved myocardial performance. CONCLUSION: Transfusion of rejuvenated red cells reduces organ injury attributable to the red cell storage lesion without adverse effects in experimental studies in vivo. The clinical benefits of this intervention remain uncertain.

Funding

This study was funded by Zimmer Biomet as part of the REDJUVENATE trial (NCT03167788) grant. Prof. Gavin J. Murphy, Dr. Marcin Wozniak and Mrs. Tracy Kumar are funded by the British Heart Foundation (CH/12/1/29419).

History

Citation

Vox Sang, 2018, 113 (6), pp. 509-529

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences

Version

  • AM (Accepted Manuscript)

Published in

Vox Sang

Publisher

Wiley

eissn

1423-0410

Acceptance date

2018-04-09

Copyright date

2018

Available date

2019-06-04

Publisher version

https://onlinelibrary.wiley.com/doi/full/10.1111/vox.12666

Notes

The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC